Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

Bibliographic Details
Main Authors:	Carol, Hernan, Boehm, Ingrid, Reynolds, C. Patrick, Kang, Min H., Maris, John M., Morton, Christopher L., Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Wu, Jianrong, Wozniak, Amy E., Yang, Yu, Manfredi, Mark, Ecsedy, Jeffrey, Wang, Jianmin, Neale, Geoffrey, Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Format:	Online
Language:	English
Published:	Springer-Verlag 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215888/

Similar Items

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
by: Kelly, Kevin R, et al.
Published: (2011)

MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
by: Nair, Jayasree S., et al.
Published: (2016)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
by: Falchook, Gerald S., et al.
Published: (2015)

The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy
by: Asteriti, Italia Anna, et al.
Published: (2014)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
by: Kelly, Kevin R., et al.
Published: (2013)

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
by: Goldberg, Stuart L., et al.
Published: (2014)

Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
by: Niu, Huifeng, et al.
Published: (2015)

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway
by: Niu, Ning-Kui, et al.
Published: (2015)

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
by: Li, Jin-Ping, et al.
Published: (2015)

A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma
by: Sampson, Valerie B., et al.
Published: (2013)

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
by: Visconte, Valeria, et al.
Published: (2015)

Auroras migrantes = Auroras in migration
by: Cury, Maria Zilda Ferreira
Published: (2015-01-01)

Targeting 4 mln visitors by yearend, 21 November 2012
by: The Borneo, Post
Published: (2012)

MLN51 Stimulates the RNA-Helicase Activity of eIF4AIII
by: Noble, Christian G., et al.
Published: (2007)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
by: Wolenski, F S, et al.
Published: (2015)

Broad and potent antiviral activity of the NAE inhibitor MLN4924
by: Le-Trilling, Vu Thuy Khanh, et al.
Published: (2016)

Simm Technology secures 3mln USD order from UK's Graphic
Published: (2004)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
by: Tavanti, E, et al.
Published: (2013)

Aurora Metals
Published: (1998)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
by: Malhab, Lara J. Bou, et al.
Published: (2016)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
by: Cozzolino, Mario, et al.
Published: (2014)

Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle
by: Hochegger, Helfrid, et al.
Published: (2013)

Overexpression of Aurora-C interferes with the spindle checkpoint by promoting the degradation of Aurora-B
by: Lin, B-W, et al.
Published: (2014)

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
by: Hartsink-Segers, S A, et al.
Published: (2013)

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
by: Gavriilidis, Paschalis, et al.
Published: (2015)

Aurora B goes the distance
by: Leslie, Mitch
Published: (2011)

Aurora B is no Ska fan
by: Leslie, Mitch
Published: (2012)

Morphologies of omega band auroras
by: Natsuo Sato, et al.
Published: (2017-08-01)

Demystifying Aurora B
by: Sedwick, Caitlin
Published: (2015)

Source of the dayside cusp aurora
by: Mende, S. B., et al.
Published: (2016)

Aurora Textile Company
by: Kenneth M., Eades, et al.
Published: (2017)

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
by: Michaelis, Martin, et al.
Published: (2014)

Pharmacodynamics in hypothermia
by: Tveita, Torkjel
Published: (2012)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
by: Geary, Richard S., et al.
Published: (2015)

MLN51 and GM-CSF involvement in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis
by: Jang, Jinah, et al.
Published: (2006)

Imaging Pulmonary NF-kappaB Activation and Therapeutic Effects of MLN120B and TDZD-8
by: Ansaldi, Dan, et al.
Published: (2011)

MLN64 Transport to the Late Endosome Is Regulated by Binding to 14-3-3 via a Non-canonical Binding Site
by: Liapis, Anastasia, et al.
Published: (2012)

The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme
by: Yang, Dong, et al.
Published: (2012)

A Multi-Parametric Imaging Investigation of the Response of C6 Glioma Xenografts to MLN0518 (Tandutinib) Treatment
by: Boult, Jessica K. R., et al.
Published: (2013)

Correction: A Multi-Parametric Imaging Investigation of the Response of C6 Glioma Xenografts to MLN0518 (Tandutinib) Treatment
by: Boult, Jessica K. R., et al.
Published: (2013)